NEW YORK (GenomeWeb) – Danaher today announced a definitive merger agreement to purchase Pall in an all-cash deal totaling approximately $13.8 billion. 

Under the terms of the deal, which is expected to be completed around the end of the year, Danaher will pay $127.20 for each share of Pall's stock. The $13.8 billion price tag includes assumed debt and is net of acquired cash. The boards of Danaher and Pall have unanimously approved the merger. 

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

CNN reports that researchers have tied a new variant to opioid addiction risk.

Organoids derived from patients' tumors may help determine what chemotherapy treatment patients would benefit from, according to New Scientist.

An initiative from GenomeAsia 100K hopes to increase the number of South Asians in genetic research, according to NBC News.

In Science this week: genomic analysis of ancient and modern horses indicates population turnover, and more.